Latest news

• Bayer gets EU nod for prostate cancer drug Nubeqa

  The EC has approved Nubeqa (darolutamide) as a treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC), which has become an increasingly competitive therapy area. ... With the authorisation of darolutamide in the EU,

• Givlaari, Rybelsus lead crowded CHMP recommendations

  Other notable recommendations include Bayer’s Nubeqa (darolutamide), which has been recommended for approval as a treatment for prostate cancer.

• J&J gets EMA nod for wider use of Erleada in prostate cancer

  So far, Erleada – which was also approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) a few months ahead of Xtandi and Bayer’s recently-approved competitor  Nubeqa (darolutamide) –

• J&J puts pressure on rivals with new Erleada okay in prostate cancer

  Since then, Bayer and Orion’s  Nubeqa(darolutamide) has also joined the fray in nmCRPC after an FDA approval in July, adding to the competitive pressure in that indication.

• Bayer bags FDA nod for early prostate cancer drug darolutamide

  Meanwhile, another phase 3 clinical trial called ARASENS is ongoing and is testing darolutamide in metastatic hormone-sensitive prostate cancer (HSPC) with results due in 2022. ... Bayer says it has also submitted darolutamide in the EU, Japan, and